XASXPER
Market cap31mUSD
Jan 29, Last price
0.06AUD
Name
Antisense Therapeutics Ltd
Chart & Performance
Profile
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | |||||||||
Revenues | 1,580 -11.14% | 1,778 207.72% | |||||||
Cost of revenue | 14,573 | 8,664 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (12,993) | (6,887) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (377) | 22 | |||||||
Tax Rate | |||||||||
NOPAT | (12,616) | (6,909) | |||||||
Net income | (11,380) 95.06% | (5,834) -27.68% | |||||||
Dividends | (79) | ||||||||
Dividend yield | 0.17% | ||||||||
Proceeds from repurchase of equity | 21,101 | ||||||||
BB yield | -44.36% | ||||||||
Debt | |||||||||
Debt current | 94 | 94 | |||||||
Long-term debt | 190 | 361 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 7 | 1 | |||||||
Net debt | (10,683) | (18,778) | |||||||
Cash flow | |||||||||
Cash from operating activities | (8,151) | (7,805) | |||||||
CAPEX | (29) | (4) | |||||||
Cash from investing activities | (29) | (4) | |||||||
Cash from financing activities | (85) | 21,022 | |||||||
FCF | (11,650) | (7,830) | |||||||
Balance | |||||||||
Cash | 10,967 | 19,233 | |||||||
Long term investments | |||||||||
Excess cash | 10,888 | 19,144 | |||||||
Stockholders' equity | 9,976 | 21,141 | |||||||
Invested Capital | 149 | 2,226 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 634,294 | 634,294 | |||||||
Price | 0.06 -21.33% | 0.08 -61.54% | |||||||
Market cap | 37,423 -21.33% | 47,572 -54.90% | |||||||
EV | 26,740 | 28,794 | |||||||
EBITDA | (12,898) | (6,797) | |||||||
EV/EBITDA | |||||||||
Interest | 22 | ||||||||
Interest/NOPBT |